ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Diagnostic value of fluid-based non-amyloid biomarkers for Alzheimer's disease and related dementias in a clinic-based cohort from South Asia.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Blood level of β-amyloid, Tau, and p-Tau in mild cognitive impairment and Alzheimer disease: A follow up study.The Indian journal of medical research · 2026Article
- Disease-Modifying Drugs for Alzheimer's Disease: Bending the Curve.Annals of Indian Academy of Neurology · 2025Article
- Diagnostic value of fluid-based non-amyloid biomarkers for Alzheimer's disease and related dementias in a clinic-based cohort from South Asia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising dementia burden and limited knowledge of fluid biomarkers in South Asians highlights this study's aim on evaluating their utility for the diagnosis of Alzheimer's disease and related dementias (ADRD).
methodsParticipants with ADRD were recruited from a cognitive disorders clinic in India. We performed cognitive assessments and severity evaluations using standard tests. Serum and cerebrospinal fluid (CSF) levels of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), total tau, and ubiquitin C-terminal hydrolase L1 (UCHL1) were quantified using a Simoa HD analyzer.
resultsAmong the 101 participants, serum GFAP and NfL levels were significantly greater in dementia participants ( DISCUSSION: Our results emphasize the role of fluid biomarkers in diagnosing dementia in low-resource settings in South Asians. Highlights: Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels were significantly greater in patients with dementia than in healthy controls.Significant correlation was observed between the serum and cerebrospinal fluid levels of GFAP, NfL, and total tau independent of the baseline demographics or co-morbidities, indicating their potential role in clinical practice.Serum biomarker levels were related to the severity of dementia.This is one of few studies on fluid-based biomarkers in diverse cohorts with Alzheimer's disease and related dementias in the South Asian cohort with limited resources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.